EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

키워드

참고문헌 (25)

1. Dillman RO, "A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer", N Engl J Med, 323, pp.940~945 (1990)
2. Furuse K, "Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer", J Clin Oncol, 17, pp.2692~2699 (1999)
3. Segawa Y, "Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer : OLCSG 0007", J Clin Oncol, 28, pp.3299~3306 (2010)
4. Yamamoto N, "Phase III study comparing second-and thirdgeneration regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer : West Japan Thoracic Oncology Group WJTOG0105", J Clin Oncol, 28, pp.3739~3745 (2010)
5. Kris MG, "Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs", JAMA, 311, pp.1998~2006 (2014)
6. Yatabe Y, "EGFR mutation testing practices within the Asia Pacific region : results of a multicenter diagnostic survey", J Thorac Oncol, 10, pp.438~445 (2015)
7. Han JY, "Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma", Lung Cancer, 85, pp.161~167 (2014)
8. Nguyen KS, "First-line treatment of EGFR-mutant non-small-cell lung cancer : the role of erlotinib and other tyrosine kinase inhibitors", Biologics, 6, pp.337~345 (2012)
9. Li F, "Role of EGFR mutation status in patients with stage III non-squamous nonsmall cell lung cancer treated with chemoradiotherapy", Zhongguo Fei Ai Za Zhi, 14, pp.715~718 (2011)
10. Mak RH, "Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC", Oncologist, 16, pp.886~895 (2011)
11. Tanaka T, "Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers", Cancer Sci, 98, pp.246~252 (2007)
12. Bradley JD, "Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer(RTOG 0617) : a randomised, two-by-two factorial phase 3 study", Lancet Oncol, 16, pp.187~199 (2015)
13. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
14. Ahn HK, "Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery", Lung Cancer, 79, pp.300~306 (2013)
15. Kelly K, "Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer : SWOG S0023", J Clin Oncol, 26, pp.2450~2456 (2008)
16. Bhutani M, "SWOG S0023 : what meets the eye may be only half the truth", J Clin Oncol, 26, pp.4848~4849 (2008)
17. Tanaka K, "EGFR mutation impact on definitive concurrent chemoradiation therapy for inoperable stage III adenocarcinoma", J Thorac Oncol, 10, pp.1720~1725 (2015)
18. Akamatsu H, "The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy", Am J Clin Oncol, 37, pp.144~147 (2014)
19. Gore EM, "Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer : primary analysis of radiation therapy oncology group study RTOG 0214", J Clin Oncol, 29, pp.272~278 (2011)
20. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
21. Ballard P, "Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity", Clin Cancer Res, 22, pp.5130~5140 (2016)
22. Antonia SJ, "Durvalumab after chemoradiotherapy in stage III nonsmall-cell lung cancer", N Engl J Med, 377, pp.1919~1929 (2017)
23. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
24. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
25. Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)

관련 논문AI추천